Zelda Therapeutics Ltd Made an agreement with Knop Laboratories
Made an agreement with Knop Laboratories: Zelda Therapeutics Ltd (ASX: ZLD) made a manufacturing and distribution agreement with Knop Laboratories. As a result, the stock rallied over 86.8% in this year to date (as of July 7th, 2017). With this move, the group would be able to fasten their clinical trial process, as there is already a certainty of product supply. This would also enable the mass production of the group’s medicines for the treatment of eczema, insomnia and autism, offering a natural alternative to many patients who suffer from these conditions. Knop is well positioned in Chile with a chain of pharmacies and there is a possibility for them to be a major distribution channel for Zelda registered medicines post their finishing of the clinical trials in insomnia, eczema and the recently announced expansion into autism. The group chose Chile for their research work as the region legal framework recognizes the importance of medical cannabis, while enables their production under strict regulatory controls for the treatment of medical conditions. The country is also a cost-effective destination for Zelda to conduct clinical trials.
To read the complete report CLICK HERE. To get your free report CLICK HERE
The advice given by Kalkine Pty Ltd and provided on this website is general information only and it does not take into account your investment objectives, financial situation or needs. You should therefore consider whether the advice is appropriate to your investment objectives, financial situation and needs before acting upon it. You should seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) as necessary before acting on any advice. Not all investments are appropriate for all people. Kalkine.com.au and associated websites are published by Kalkine Pty Ltd ABN 34 154 808 312 (Australian Financial Services License Number 425376). The information on this website has been prepared from a wide variety of sources, which Kalkine Pty Ltd, to the best of its knowledge and belief, considers accurate. You should make your own enquiries about any investments and we strongly suggest you seek advice before acting upon any recommendation. Kalkine Pty Ltd has made every effort to ensure the reliability of information contained in its newsletters and websites. All information represents our views at the date of publication and may change without notice. To the extent permitted by law, Kalkine Pty Ltd excludes all liability for any loss or damage arising from the use of this website and any information published (including any indirect or consequential loss, any data loss or data corruption). If the law prohibits this exclusion, Kalkine Pty Ltd hereby limits its liability, to the extent permitted by law to the resupply of services. There may be a product disclosure statement or other offer document for the securities and financial products we write about in Kalkine Reports. You should obtain a copy of the product disclosure statement or offer document before making any decision about whether to acquire the security or product. The link to our Terms & Conditions has been provided please go through them and also have a read of the Financial Services Guide. On the date of publishing this report (mentioned on the website), employees and/or associates of Kalkine Pty Ltd do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations.